Duality Biotherapeutics, Inc. AI Stock Analysis
Want to see HK:9606 full AI Analyst Report?
Duality Biotherapeutics, Inc. (9606) AI Stock Analysis
Duality Biotherapeutics, Inc.
(HKEX:9606)
The score is held back primarily by weak financial quality (ongoing losses, margin deterioration, and volatile equity despite recent positive cash flow) and a clearly bearish technical setup (price well below key moving averages with negative MACD). Valuation is also a drag due to the negative P/E and lack of dividend yield data.
Duality Biotherapeutics, Inc. (9606) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 10.23B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.07M
- Price to Earnings (P/E)
- -5.7
- Beta (1Y)
- 0.96
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 231
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Duality Biotherapeutics, Inc. Business Overview & Revenue Model
Company Description
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded...
How the Company Makes Money
The company’s primary ways to generate revenue typically include (i) collaboration and licensing arrangements in which it grants partners rights to develop and/or commercialize certain drug candidates in exchange for upfront payments, milestone payme...
Duality Biotherapeutics, Inc. Financial Statement Overview
Summary
Mixed fundamentals: revenue has grown meaningfully, but profitability is weak and volatile with widening net losses in 2025 and sharply lower gross margin (~31%). Balance sheet leverage is low (2025 debt-to-equity ~0.06), yet equity has been inconsistent (negative in 2022–2024, positive in 2025). Cash flow is a relative bright spot with positive operating and free cash flow in 2023–2025, though free cash flow fell sharply in 2025 and volatility remains.
Income Statement
28NegativeBalance Sheet
55NeutralCash Flow
64Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 842.13M | 1.80B | 1.94B | 1.79B | 1.60M |
| Gross Profit | -233.67M | 561.85M | 784.67M | 1.36B | 1.60M |
| EBITDA | -1.53B | -2.51B | -1.01B | -197.07M | -385.22M |
| Net Income | -1.44B | -2.53B | -1.05B | -357.51M | -387.09M |
Balance Sheet | |||||
| Total Assets | 3.51B | 3.89B | 2.09B | 1.50B | 463.74M |
| Cash, Cash Equivalents and Short-Term Investments | 3.04B | 3.43B | 1.39B | 1.13B | 375.97M |
| Total Debt | 379.46M | 149.84M | 5.29M | 5.32M | 4.67M |
| Total Liabilities | 2.06B | 1.47B | 4.11B | 2.62B | 1.23B |
| Stockholders Equity | 1.45B | 2.43B | -2.02B | -1.12B | -769.12M |
Cash Flow | |||||
| Free Cash Flow | -404.41M | 180.86M | 254.60M | 780.43M | -321.67M |
| Operating Cash Flow | -395.18M | 194.58M | 285.78M | 816.34M | -299.47M |
| Investing Cash Flow | -1.39B | -1.91B | -211.15M | -78.55M | -22.20M |
| Financing Cash Flow | 79.48M | 1.81B | -7.62M | 10.82M | 451.46M |
Duality Biotherapeutics, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9606, the sentiment is Negative. The current price of 108.40 is below the 20-day moving average (MA) of 127.74, below the 50-day MA of 164.60, and below the 200-day MA of 230.80, indicating a bearish trend. The MACD of -19.56 indicates Negative momentum. The RSI at 31.54 is Neutral, neither overbought nor oversold. The STOCH value of 63.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9606.
Duality Biotherapeutics, Inc. Peers Comparison
Overall Rating
HK:180172Outperform
HK:999566Neutral
HK:269664.6Neutral
HK:992648Neutral- HK:960647Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1801 | 72Outperform | HKD 154.34B | 104.31 | 6.06% | ― | 42.64% | 9.67% |
| HK:9995 | 66Neutral | HKD 56.21B | 8.51 | 105.60% | ― | 292.84% | ― |
| HK:2696 | 65Neutral | HKD 27.35B | 26.69 | 20.41% | ― | 32.63% | 8.74% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:9926 | 48Neutral | HKD 83.86B | -70.81 | -10.86% | ― | 42.47% | -15.80% |
| HK:9606 | 47Neutral | HKD 9.86B | -5.74 | -74.20% | ― | ― | ― |
| HK:1877 | 41Neutral | HKD 32.01B | -73.23 | -7.23% | ― | 35.82% | 54.40% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9606 | Duality Biotherapeutics, Inc. | 108.40 | -222.80 | -67.27% | |
| HK:1801 | Innovent Biologics | 86.80 | -5.15 | -5.60% | |
| HK:9926 | Akeso, Inc. | 88.60 | -32.90 | -27.08% | |
| HK:9995 | RemeGen Co. Ltd. Class H | 69.95 | -14.55 | -17.22% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.67 | -10.63 | -40.42% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.88 | -14.87 | -22.97% |
Duality Biotherapeutics, Inc. Corporate Events
Duality Biotherapeutics Reports Modest Phase 3 Gain for Key Breast Cancer Drug
Duality Biotherapeutics, Inc. announced that its DYNASTY-Breast02 global Phase 3 trial of trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer met its primary endpoint, showing a statistically significant but modest improvement in progress...
Duality Biotherapeutics Narrows Loss as ADC Pipeline Reaches Key Milestones
Duality Biotherapeutics reported interim unaudited results for the six months ended June 30, 2026, showing revenue of RMB219.3 million, or adjusted revenue of RMB510 million after accounting for a one-off U.S. option impact. The company posted a narr...
Duality Biotherapeutics Strikes Billion-Dollar ADC Collaboration with Genentech
Duality Biotherapeutics has entered a global research and development collaboration and license agreement with Genentech, part of the Roche Group, to co-develop next-generation antibody-drug conjugates based on its proprietary DUPAC payload platform...
Duality Biotherapeutics Sets Board Meeting to Approve 2026 Interim Results
Duality Biotherapeutics, Inc. has scheduled a board meeting for August 28, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The forthcoming publication of these results will give investors and other sta...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026